Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

@article{Perez2008ImpactMA,
  title={Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer},
  author={Edith A. Perez},
  journal={Breast Cancer Research and Treatment},
  year={2008},
  volume={114},
  pages={195-201}
}
  • E. Perez
  • Published 1 March 2009
  • Medicine, Biology
  • Breast Cancer Research and Treatment
Despite advances in treatment of patients with metastatic breast cancer (MBC), prognosis remains poor and median survival is 2–3 years. Resistance to antineoplastics mediated by many factors, potentially including overexpression of drug efflux proteins or altered β-tubulin isotype expression limits the effectiveness of MBC chemotherapy. Capecitabine, approved for anthracycline- and taxane-resistant MBC, has produced modest responses, highlighting the need for more effective treatments for MBC… 
View on Springer
repositoryeffetti.it
86 Citations
Highly Influential Citations
4
Background Citations
36

86 Citations

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
  • D. Yardley
  • Medicine, Biology
    International journal of breast cancer
  • 2013
TLDR
The aim of this paper is to review mechanisms of resistance to common chemotherapy agents and to consider current combination treatment options for heavily pretreated and/or drug-resistant patients with MBC.
An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
TLDR
VERU-111 is a promising new generation of tubulin inhibitor for the treatment of TNBC and may be effective in patients who progress on taxanes, as well as efficacious in a taxane-resistant model of metastatic TNBC.
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.
Etirinotecan pegol for the treatment of breast cancer
TLDR
Etirinotecan pegol demonstrates anti-tumor activity and improved tolerability in patients with refractory metastatic breast cancer, allowing the challenge of resistance in the advanced disease setting to be addressed.
DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery.
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
TLDR
Available literature evidence on different chemotherapy agents used beyond the first-line, in locally advanced or MBC patients, including rechallenge with anthracyclines and taxanes, antimetabolite and antimicrotubule agents, such as vinorelbine, capecitabine, eribulin, ixabepilone, and the newest developed agents, are summarized.
Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies
  • N. Wind, I. Holen
  • Biology, Medicine
    International journal of breast cancer
  • 2011
TLDR
Evidence of the potential roles of key molecules associated with breast cancer MDR are summarized and possible explanations for why despite several decades of research, the precise role of ABC transporters remains elusive are provided.
Targeted multidrug delivery system to overcome chemoresistance in breast cancer
TLDR
Findings clearly indicate that tumor growth was significantly delayed in the combinational liposomal drug delivery group, suggesting that this novel combinational therapy has great potential for the treatment of patients with HER2/MDR double positive breast cancer.
Decoding novel mechanisms and emerging therapeutic strategies in breast cancer resistance.
TLDR
The chemoresistance mechanisms of miRNAs, CSCs as well as most recently documented therapeutic approaches for the treatment of Chemoresistance in breast cancer are summarized.
The multi-factorial nature of clinical multidrug resistance in cancer.
...
...

References

SHOWING 1-10 OF 71 REFERENCES
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
  • H. Thomas, H. Coley
  • Medicine, Biology
    Cancer control : journal of the Moffitt Cancer Center
  • 2003
TLDR
Third-generation P-gp inhibitors have shown promise in clinical trials and may establish the true therapeutic potential of P- gp-mediated MDR reversal, and pharmacokinetic studies to date have shown no appreciable impact on cytochrome P450 3A4 drug metabolism and no clinically significant drug interactions with common chemotherapy agents.
Mechanisms of cancer drug resistance.
The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer…
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
  • E. Thomas, H. Gómez, H. Roché
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Ixabepilone plus capecitabine demonstrates superior efficacy to cape citabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
TLDR
Twenty tRAs, selected based on modulation of paclitaxel cytotoxicity in Pgp-overexpressing MDA435/LCC6(mdr1) cells, were studied for modulation of retention and cytot toxicity of substrates of MRP-1 and BCRP as well as Pgp in established cell lines overexpressing each of these transporters.
Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
TLDR
The natural epothilones and their analogs are a novel class of microtubule-stabilizing agents that bind tubulin and result in apoptotic cell death.
The Role of Capecitabine , an Oral , Enzymatically Activated Fluoropyrimidine , in the Treatment of Metastatic Breast Cancer
TLDR
Capecitabine has become an important treatment option for patients with metastatic breast cancer that has progressed following taxane therapy, and has shown promise in anthracycline-pretreated patients, as first-line monotherapy, and as a component of combination regimens.
Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
TLDR
This review highlights the major areas of investigation as they relate to the tubulin/microtubule system and discusses opportunities that potentially exist for improved therapeutic benefit in the treatment of drug resistant disease.
Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.
Chemotherapy: what progress in the last 5 years?
  • A. Hamilton, G. Hortobagyi
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
It is 1999, during the American Society of Clinical Oncology (ASCO) Annual Meeting, and the plenary session is dedicated to the randomized studies that have failed to demonstrate a meaningful benefit…
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
  • E. Perez, G. Lerzo, G. Hortobagyi
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine, and Responses were durable and notable in patients who had not previously responded to multiple prior therapies.
...
...